Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis.

Uccelli A, Laroni A, Brundin L, Clanet M, Fernandez O, Nabavi SM, Muraro PA, Oliveri RS, Radue EW, Sellner J, Soelberg Sorensen P, Sormani MP, Wuerfel JT, Battaglia MA, Freedman MS; MESEMS study group.

Trials. 2019 May 9;20(1):263. doi: 10.1186/s13063-019-3346-z.

2.

Epstein-Barr Virus and Monoclonal Gammopathy of Clinical Significance in Autologous Stem Cell Transplantation for Multiple Sclerosis.

Mehra V, Rhone E, Widya S, Zuckerman M, Potter V, Raj K, Kulasekararaj A, McLornan D, de Lavallade H, Benson-Quarm N, Lim C, Ware S, Sudhanva M, Malik O, Nicholas R, Muraro PA, Marsh J, Mufti GJ, Silber E, Pagliuca A, Kazmi MA.

Clin Infect Dis. 2019 Jan 15. pii: ciz047. doi: 10.1093/cid/ciz047. [Epub ahead of print]

PMID:
30980715
3.

Author response: Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2019 Mar 19;92(12):586. doi: 10.1212/WNL.0000000000007128. No abstract available.

PMID:
30886076
4.

Confirmation of Specific Binding of the 18-kDa Translocator Protein (TSPO) Radioligand [18F]GE-180: a Blocking Study Using XBD173 in Multiple Sclerosis Normal Appearing White and Grey Matter.

Sridharan S, Raffel J, Nandoskar A, Record C, Brooks DJ, Owen D, Sharp D, Muraro PA, Gunn R, Nicholas R.

Mol Imaging Biol. 2019 Feb 22. doi: 10.1007/s11307-019-01323-8. [Epub ahead of print]

PMID:
30796709
5.

Autologous Hematopoietic Cell Transplantation for Treatment-Refractory Relapsing Multiple Sclerosis: Position Statement from the American Society for Blood and Marrow Transplantation.

Cohen JA, Baldassari LE, Atkins HL, Bowen JD, Bredeson C, Carpenter PA, Corboy JR, Freedman MS, Griffith LM, Lowsky R, Majhail NS, Muraro PA, Nash RA, Pasquini MC, Sarantopoulos S, Savani BN, Storek J, Sullivan KM, Georges GE.

Biol Blood Marrow Transplant. 2019 May;25(5):845-854. doi: 10.1016/j.bbmt.2019.02.014. Epub 2019 Feb 19. Review.

6.

Comprehensive Analysis of TCR-β Repertoire in Patients with Neurological Immune-mediated Disorders.

Alves Sousa AP, Johnson KR, Ohayon J, Zhu J, Muraro PA, Jacobson S.

Sci Rep. 2019 Jan 23;9(1):344. doi: 10.1038/s41598-018-36274-7.

7.

Autologous haematopoietic stem cell transplantation (aHSCT) for severe resistant autoimmune and inflammatory diseases - a guide for the generalist.

Snowden JA, Sharrack B, Akil M, Kiely DG, Lobo A, Kazmi M, Muraro PA, Lindsay JO.

Clin Med (Lond). 2018 Aug;18(4):329-334. doi: 10.7861/clinmedicine.18-4-329.

8.

Hematopoietic stem cell therapy for autoimmune diseases - Clinical experience and mechanisms.

Alexander T, Farge D, Badoglio M, Lindsay JO, Muraro PA, Snowden JA; Autoimmune Diseases Working Party (ADWP) of the European Society for Blood and Marrow Transplantation (EBMT).

J Autoimmun. 2018 Aug;92:35-46. doi: 10.1016/j.jaut.2018.06.002. Epub 2018 Jun 20. Review.

PMID:
29934135
9.

The cortical damage, early relapses, and onset of the progressive phase in multiple sclerosis.

Scalfari A, Romualdi C, Nicholas RS, Mattoscio M, Magliozzi R, Morra A, Monaco S, Muraro PA, Calabrese M.

Neurology. 2018 Jun 12;90(24):e2107-e2118. doi: 10.1212/WNL.0000000000005685. Epub 2018 May 16.

10.

Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance.

Muraro PA, Scolding NJ, Fox RJ.

Neurology. 2018 May 1;90(18):819-820. doi: 10.1212/WNL.0000000000005409. Epub 2018 Mar 30. No abstract available.

PMID:
29602911
11.

Intense immunosuppression followed by autologous haematopoietic stem cell transplantation as a therapeutic strategy in aggressive forms of multiple sclerosis.

Mancardi G, Sormani MP, Muraro PA, Boffa G, Saccardi R.

Mult Scler. 2018 Mar;24(3):245-255. doi: 10.1177/1352458517742532. Epub 2017 Nov 10.

12.

Programmed death 1 is highly expressed on CD8+ CD57+ T cells in patients with stable multiple sclerosis and inhibits their cytotoxic response to Epstein-Barr virus.

Cencioni MT, Magliozzi R, Nicholas R, Ali R, Malik O, Reynolds R, Borsellino G, Battistini L, Muraro PA.

Immunology. 2017 Dec;152(4):660-676. doi: 10.1111/imm.12808. Epub 2017 Sep 21.

13.

Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis.

Muraro PA, Martin R, Mancardi GL, Nicholas R, Sormani MP, Saccardi R.

Nat Rev Neurol. 2017 Jul;13(7):391-405. doi: 10.1038/nrneurol.2017.81. Epub 2017 Jun 16. Review.

14.

Autologous hematopoietic stem cell transplantation in multiple sclerosis: A meta-analysis.

Sormani MP, Muraro PA, Schiavetti I, Signori A, Laroni A, Saccardi R, Mancardi GL.

Neurology. 2017 May 30;88(22):2115-2122. doi: 10.1212/WNL.0000000000003987. Epub 2017 Apr 28. Erratum in: Neurology. 2017 Jul 11;89(2):215.

PMID:
28455383
15.

Progress and prospects for the use and the understanding of the mode of action of autologous hematopoietic stem cell transplantation in the treatment of multiple sclerosis.

Collins F, Kazmi M, Muraro PA.

Expert Rev Clin Immunol. 2017 Jun;13(6):611-622. doi: 10.1080/1744666X.2017.1297232. Epub 2017 Mar 20. Review.

16.

Long-term Outcomes After Autologous Hematopoietic Stem Cell Transplantation for Multiple Sclerosis.

Muraro PA, Pasquini M, Atkins HL, Bowen JD, Farge D, Fassas A, Freedman MS, Georges GE, Gualandi F, Hamerschlak N, Havrdova E, Kimiskidis VK, Kozak T, Mancardi GL, Massacesi L, Moraes DA, Nash RA, Pavletic S, Ouyang J, Rovira M, Saiz A, Simoes B, Trnený M, Zhu L, Badoglio M, Zhong X, Sormani MP, Saccardi R; Multiple Sclerosis–Autologous Hematopoietic Stem Cell Transplantation (MS-AHSCT) Long-term Outcomes Study Group.

JAMA Neurol. 2017 Apr 1;74(4):459-469. doi: 10.1001/jamaneurol.2016.5867.

17.

High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Steinmiller KC, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stuve O, Arnold DL, Wener MH, Georges GE, Wundes A, Kraft GH, Bowen JD.

Neurology. 2017 Feb 28;88(9):842-852. doi: 10.1212/WNL.0000000000003660. Epub 2017 Feb 1.

18.

Analysis of ageing-associated grey matter volume in patients with multiple sclerosis shows excess atrophy in subcortical regions.

Bishop CA, Newbould RD, Lee JS, Honeyfield L, Quest R, Colasanti A, Ali R, Mattoscio M, Cortese A, Nicholas R, Matthews PM, Muraro PA, Waldman AD.

Neuroimage Clin. 2016 Nov 9;13:9-15. eCollection 2017.

19.

Intrathecal T-cell clonal expansions in patients with multiple sclerosis.

de Paula Alves Sousa A, Johnson KR, Nicholas R, Darko S, Price DA, Douek DC, Jacobson S, Muraro PA.

Ann Clin Transl Neurol. 2016 Apr 20;3(6):422-33. doi: 10.1002/acn3.310. eCollection 2016 Jun.

20.

A Comparison of Magnetization Transfer Methods to Assess Brain and Cervical Cord Microstructure in Multiple Sclerosis.

Lema A, Bishop C, Malik O, Mattoscio M, Ali R, Nicholas R, Muraro PA, Matthews PM, Waldman AD, Newbould RD.

J Neuroimaging. 2017 Mar;27(2):221-226. doi: 10.1111/jon.12377. Epub 2016 Aug 5.

21.

NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs.

Sormani MP, Muraro PA, Saccardi R, Mancardi G.

Mult Scler. 2017 Feb;23(2):201-204. doi: 10.1177/1352458516645670. Epub 2016 Jul 11. Review.

PMID:
27207454
22.

The relationship of age with the clinical phenotype in multiple sclerosis.

Scalfari A, Lederer C, Daumer M, Nicholas R, Ebers GC, Muraro PA.

Mult Scler. 2016 Nov;22(13):1750-1758. Epub 2016 Feb 11.

PMID:
26869531
23.

Hippocampal Neuroinflammation, Functional Connectivity, and Depressive Symptoms in Multiple Sclerosis.

Colasanti A, Guo Q, Giannetti P, Wall MB, Newbould RD, Bishop C, Onega M, Nicholas R, Ciccarelli O, Muraro PA, Malik O, Owen DR, Young AH, Gunn RN, Piccini P, Matthews PM, Rabiner EA.

Biol Psychiatry. 2016 Jul 1;80(1):62-72. doi: 10.1016/j.biopsych.2015.11.022. Epub 2015 Dec 5.

24.

Hematopoietic mobilization: Potential biomarker of response to natalizumab in multiple sclerosis.

Mattoscio M, Nicholas R, Sormani MP, Malik O, Lee JS, Waldman AD, Dazzi F, Muraro PA.

Neurology. 2015 Apr 7;84(14):1473-82. doi: 10.1212/WNL.0000000000001454. Epub 2015 Mar 11.

25.

Andiamo! Moving forward with autologous hematopoietic transplantation for highly active MS.

Muraro PA.

Neurology. 2015 Mar 10;84(10):968-9. doi: 10.1212/WNL.0000000000001347. Epub 2015 Feb 11. No abstract available.

PMID:
25672922
26.

High-dose immunosuppressive therapy and autologous hematopoietic cell transplantation for relapsing-remitting multiple sclerosis (HALT-MS): a 3-year interim report.

Nash RA, Hutton GJ, Racke MK, Popat U, Devine SM, Griffith LM, Muraro PA, Openshaw H, Sayre PH, Stüve O, Arnold DL, Spychala ME, McConville KC, Harris KM, Phippard D, Georges GE, Wundes A, Kraft GH, Bowen JD.

JAMA Neurol. 2015 Feb;72(2):159-69. doi: 10.1001/jamaneurol.2014.3780.

27.

SCT for severe autoimmune diseases: consensus guidelines of the European Society for Blood and Marrow Transplantation for immune monitoring and biobanking.

Alexander T, Bondanza A, Muraro PA, Greco R, Saccardi R, Daikeler T, Kazmi M, Hawkey C, Simoes BP, Leblanc K, Fibbe WE, Moore J, Snarski E, Martin T, Hiepe F, Velardi A, Toubert A, Snowden JA, Farge D.

Bone Marrow Transplant. 2015 Feb;50(2):173-80. doi: 10.1038/bmt.2014.251. Epub 2014 Nov 10. Review.

28.

Autologous haematopoietic stem cell transplantation reduces abnormalities in the expression of immune genes in multiple sclerosis.

de Paula A Sousa A, Malmegrim KC, Panepucci RA, Brum DS, Barreira AA, Carlos Dos Santos A, Araújo AG, Covas DT, Oliveira MC, Moraes DA, Pieroni F, Barros GM, Simões BP, Nicholas R, Burt RK, Voltarelli JC, Muraro PA.

Clin Sci (Lond). 2015 Jan;128(2):111-20. doi: 10.1042/CS20140095.

PMID:
25116724
29.

Regulatory B cells are enriched within the IgM memory and transitional subsets in healthy donors but are deficient in chronic GVHD.

Khoder A, Sarvaria A, Alsuliman A, Chew C, Sekine T, Cooper N, Mielke S, de Lavallade H, Muftuoglu M, Fernandez Curbelo I, Liu E, Muraro PA, Alousi A, Stringaris K, Parmar S, Shah N, Shaim H, Yvon E, Molldrem J, Rouce R, Champlin R, McNiece I, Mauri C, Shpall EJ, Rezvani K.

Blood. 2014 Sep 25;124(13):2034-45. doi: 10.1182/blood-2014-04-571125. Epub 2014 Jul 22.

30.

Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis.

Newbould RD, Nicholas R, Thomas CL, Quest R, Lee JS, Honeyfield L, Colasanti A, Malik O, Mattoscio M, Matthews PM, Sormani MP, Waldman AD, Muraro PA.

Neuroimage Clin. 2014 Mar 31;4:641-8. doi: 10.1016/j.nicl.2014.02.004. eCollection 2014.

31.

In Vivo Assessment of Brain White Matter Inflammation in Multiple Sclerosis with (18)F-PBR111 PET.

Colasanti A, Guo Q, Muhlert N, Giannetti P, Onega M, Newbould RD, Ciccarelli O, Rison S, Thomas C, Nicholas R, Muraro PA, Malik O, Owen DR, Piccini P, Gunn RN, Rabiner EA, Matthews PM.

J Nucl Med. 2014 Jul;55(7):1112-8. doi: 10.2967/jnumed.113.135129. Epub 2014 Jun 5.

32.

T cell repertoire following autologous stem cell transplantation for multiple sclerosis.

Muraro PA, Robins H, Malhotra S, Howell M, Phippard D, Desmarais C, de Paula Alves Sousa A, Griffith LM, Lim N, Nash RA, Turka LA.

J Clin Invest. 2014 Mar;124(3):1168-72. doi: 10.1172/JCI71691. Epub 2014 Feb 17.

33.

Premature immune senescence in children with MS: Too young to go steady.

Bar-Or A, Muraro PA.

Neurology. 2013 Aug 27;81(9):778-9. doi: 10.1212/WNL.0b013e3182a2dd3f. Epub 2013 Aug 2. No abstract available.

PMID:
23911757
34.

Non-myeloablative autologous haematopoietic stem cell transplantation expands regulatory cells and depletes IL-17 producing mucosal-associated invariant T cells in multiple sclerosis.

Abrahamsson SV, Angelini DF, Dubinsky AN, Morel E, Oh U, Jones JL, Carassiti D, Reynolds R, Salvetti M, Calabresi PA, Coles AJ, Battistini L, Martin R, Burt RK, Muraro PA.

Brain. 2013 Sep;136(Pt 9):2888-903. doi: 10.1093/brain/awt182. Epub 2013 Jul 17.

35.

Drugs in development for relapsing multiple sclerosis.

Ali R, Nicholas RS, Muraro PA.

Drugs. 2013 May;73(7):625-50. doi: 10.1007/s40265-013-0030-6. Review.

PMID:
23609782
36.

Onset of secondary progressive phase and long-term evolution of multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Muraro PA, Ebers GC.

J Neurol Neurosurg Psychiatry. 2014 Jan;85(1):67-75. doi: 10.1136/jnnp-2012-304333. Epub 2013 Mar 13.

PMID:
23486991
37.

Early relapses, onset of progression, and late outcome in multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Deluca GC, Muraro PA, Ebers GC.

JAMA Neurol. 2013 Feb;70(2):214-22. doi: 10.1001/jamaneurol.2013.599.

PMID:
23407713
38.

A web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.

Galea I, Lederer C, Neuhaus A, Muraro PA, Scalfari A, Koch-Henriksen N, Heesen C, Koepke S, Stellmann P, Albrecht H, Winkelmann A, Weber F, Bahn E, Hauser M, Edan G, Ebers G, Daumer M.

Eur J Neurol. 2013 Jul;20(7):1107-9. doi: 10.1111/ene.12016. Epub 2012 Dec 7.

39.

Meningeal inflammation plays a role in the pathology of primary progressive multiple sclerosis.

Choi SR, Howell OW, Carassiti D, Magliozzi R, Gveric D, Muraro PA, Nicholas R, Roncaroli F, Reynolds R.

Brain. 2012 Oct;135(Pt 10):2925-37. doi: 10.1093/brain/aws189. Epub 2012 Aug 20.

PMID:
22907116
40.

Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research.

Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1471-8. doi: 10.1016/j.bbmt.2012.06.003. Epub 2012 Jun 13.

41.

Primary progressive multiple sclerosis developing in the context of young onset Parkinson's disease.

Sadnicka A, Sheerin UM, Kaplan C, Molloy S, Muraro PA.

Mult Scler. 2013 Jan;19(1):123-5. doi: 10.1177/1352458512445942. Epub 2012 Apr 20.

PMID:
22523156
42.

A prospective, randomized, controlled trial of autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: a position paper.

Saccardi R, Freedman MS, Sormani MP, Atkins H, Farge D, Griffith LM, Kraft G, Mancardi GL, Nash R, Pasquini M, Martin R, Muraro PA; European Blood and Marrow Transplantation Group; Center for International Blood and Marrow Research; HSCT in MS International Study Group.

Mult Scler. 2012 Jun;18(6):825-34. doi: 10.1177/1352458512438454. Epub 2012 Mar 1.

43.

Autologous hematopoietic stem cell transplantation for autoimmune disease--is it now ready for prime time?

Atkins HL, Muraro PA, van Laar JM, Pavletic SZ.

Biol Blood Marrow Transplant. 2012 Jan;18(1 Suppl):S177-83. doi: 10.1016/j.bbmt.2011.11.020. Review.

44.

Age and disability accumulation in multiple sclerosis.

Scalfari A, Neuhaus A, Daumer M, Ebers GC, Muraro PA.

Neurology. 2011 Sep 27;77(13):1246-52. doi: 10.1212/WNL.0b013e318230a17d. Epub 2011 Sep 14.

45.

Development of oral immunomodulatory agents in the management of multiple sclerosis.

Nicholas R, Giannetti P, Alsanousi A, Friede T, Muraro PA.

Drug Des Devel Ther. 2011;5:255-74. doi: 10.2147/DDDT.S10498. Epub 2011 May 10. Review.

46.

Resetting autoimmunity in the nervous system: The role of hematopoietic stem cell transplantation.

Muraro PA, Abrahamsson SV.

Curr Opin Investig Drugs. 2010 Nov;11(11):1265-75.

PMID:
21157646
47.

Positron emission tomography imaging in multiple sclerosis-current status and future applications.

Kiferle L, Politis M, Muraro PA, Piccini P.

Eur J Neurol. 2011 Feb;18(2):226-31. doi: 10.1111/j.1468-1331.2010.03154.x. Review.

PMID:
20636368
48.

The natural history of multiple sclerosis: a geographically based study 10: relapses and long-term disability.

Scalfari A, Neuhaus A, Degenhardt A, Rice GP, Muraro PA, Daumer M, Ebers GC.

Brain. 2010 Jul;133(Pt 7):1914-29. doi: 10.1093/brain/awq118. Epub 2010 Jun 9.

49.

Hematopoietic stem cell transplantation for multiple sclerosis: collaboration of the CIBMTR and EBMT to facilitate international clinical studies.

Pasquini MC, Griffith LM, Arnold DL, Atkins HL, Bowen JD, Chen JT, Freedman MS, Kraft GH, Mancardi GL, Martin R, Muraro PA, Nash RA, Racke MK, Storek J, Saccardi R.

Biol Blood Marrow Transplant. 2010 Aug;16(8):1076-83. doi: 10.1016/j.bbmt.2010.03.012. Epub 2010 Mar 18. Review.

50.

Autologous haematopoietic stem cell transplantation for secondary progressive multiple sclerosis: an exploratory cost-effectiveness analysis.

Tappenden P, Saccardi R, Confavreux C, Sharrack B, Muraro PA, Mancardi GL, Kozak T, Farge-Bancel D, Madan J, Rafia R, Akehurst R, Snowden J.

Bone Marrow Transplant. 2010 Jun;45(6):1014-21. doi: 10.1038/bmt.2009.305. Epub 2009 Oct 26.

PMID:
19855441

Supplemental Content

Loading ...
Support Center